A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19+tumor cells-Reference-Cited by-同舟云学术

A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19+tumor cells

Published:2015-04-15 Issue:3 Volume:7 Page:584-604
ISSN:1942-0862
Container-title:mAbs
language:en
Short-container-title:mAbs

Author:

Reusch Uwe,Duell Johannes,Ellwanger Kristina,Herbrecht Carmen,Knackmuss Stefan HJ,Fucek Ivica,Eser Markus,McAleese Fionnuala,Molkenthin Vera,Le Gall Fabrice,Topp Max,Little Melvyn,Zhukovsky Eugene A

Publisher

Informa UK Limited

Subject

Immunology,Immunology and Allergy

Link

http://www.tandfonline.com/doi/pdf/10.1080/19420862.2015.1029216

Reference40 articles.

1. Rituximab The First Monoclonal Antibody Approved for the Treatment of Lymphoma

2. The future of anti-CD20 monoclonal antibodies: are we making progress?

3. Update on obinutuzumab in the treatment of B-cell malignancies

4. Mogamulizumab and the treatment of CCR4-positive T-cell lymphomas

5. Potent In vitro and In vivo Activity of an Fc-Engineered Anti-CD19 Monoclonal Antibody against Lymphoma and Leukemia

Cited by 119 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phage display for discovery of anticancer antibodies;New Biotechnology;2024-11

2. Bispecific and multispecific antibodies in oncology: opportunities and challenges;Nature Reviews Clinical Oncology;2024-05-31

3. Control of acute myeloid leukemia and generation of immune memory in vivo using AMV564, a bivalent bispecific CD33 x CD3 T cell engager;PLOS ONE;2024-05-02

4. T-Cell Engagers—The Structure and Functional Principle and Application in Hematological Malignancies;Cancers;2024-04-20

5. RUBY® – a tetravalent (2+2) bispecific antibody format with excellent functionality and IgG-like stability, pharmacology and developability properties;mAbs;2024-03-25